MYC rearrangement is also frequently present (in 39% of cases), resulting in an immunoblastic variant with higher proliferation and cell growth with a more aggressive course of disease [1,11-13]. Alterations in epigenetic genes such as TET2, ASXL1, SRSF2, IDH2, among others, show an association with other myeloid neoplasms. This evidence concerns the gene MYC and myeloid neoplasm.